63074-08-8 Usage
Description
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride, also known as Terazosin hydrochloride, is a highly water-soluble antihypertensive agent with a structure and profile closely related to that of prazosin. It is a structural congener of prazosin hydrochloride and possesses similar selective properties of specifically inhibiting 1-adrenergic receptors. The drug is slightly less potent than prazosin hydrochloride but has a longer half-life, which allows for once-daily dosing to control hypertension in many patients.
Uses
Used in Pharmaceutical Industry:
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride is used as an antihypertensive agent for the treatment of hypertension. Its selective inhibition of 1-adrenergic receptors and longer half-life make it a suitable choice for once-daily dosing, improving patient compliance and effectiveness in managing blood pressure.
Used in Research and Development:
Terazosin hydrochloride has been used for orthogonality and similarity analysis using reversed-phase chromatographic studies. It has also been employed in the evaluation of chemometric techniques to determine orthogonality and similarity in chromatographic methods, contributing to the advancement of pharmaceutical research and development.
Used in Medical Treatments:
Under the brand name Hytrin, Terazosin hydrochloride is used in the medical field for the treatment of hypertension. Its once-daily dosing regimen and effectiveness in controlling blood pressure make it a preferred choice for many patients suffering from high blood pressure.
Biological Activity
α 1 - and α 2B -adrenoceptor antagonist (K i values are 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α 1A , α 1B , α 1D , α 2B , α 2A and α 2C receptors respectively). Antihypertensive following oral or intravenous administration in vivo .
Biochem/physiol Actions
α1-adrenoceptor antagonist.
References
References/Citations
1) Hancock et al. (1995), Actions of terazosin and its enantiomers at subtypes of alpha-1 and alpha-2 adrenoceptors in vitro; Recept. Signal Transduct. Res., 15 863
2) Kyncl et al. (1986), Pharmacology of terazosin; Am. J. Med., 80 12
3) Shionoiri et al. (1994), Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study; Am. J. Med. Sci., 307 Suppl 1 S91
4) Pan et al. (2003), Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells; J. Urol., 169 724
5) Chen et al. (2015), Terazosin activates Pgk1 and HSP90 to promote stress resistance; Nat. Chem. Biol., 11 19
Check Digit Verification of cas no
The CAS Registry Mumber 63074-08-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,3,0,7 and 4 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 63074-08:
(7*6)+(6*3)+(5*0)+(4*7)+(3*4)+(2*0)+(1*8)=108
108 % 10 = 8
So 63074-08-8 is a valid CAS Registry Number.
InChI:InChI=1/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
